Introduction. Treatment strategies for patients with SLE have been a topic for discussion in period of Covid 19 pandemic due to the consideration that some of the drugs are influencing the immune disease. Material and methods. In this analytical study, the PUBMED database was used to select bibliographic sources using specific keywords (Covid-19, Systemic lupus erythematosus, treatment), resulting in 145 articles. Results. Studies have shown that SLE patients who contract COVID-19 are at increased risk of developing severe disease and complications. Steroids are largely used for acute management of SLE and Covid-19 infection apart, but there are not sufficient data to confirm efficiency of GCS in SLE and Covid-19. There are many controversial studies about HCQ treatment. Currently, there is no evidence that HCQ improves outcomes for COVID-19 in patients with SLE. However, in patients already taking HCQ as basic treatment, it was shown no negative effect on infection, hospitalisation and severe infection rate. There are insufficient data about mycophenolate mofetil, cyclophosphamide and azathioprine. Some sources suggest that treatment with CYC increase the susceptibility for infections, others do not confirm this statement. The basic treatment with immunosuppressive drugs is recommended to be continued in case of Covid-19 infection. Conclusion. The vigilant management of the disease is essential in patients with SLE in the period of Covid-19 pandemic. No stop of treatment strategy is recommended in case of infection.